{"groups":[{"description":"Radiation therapy: 60 Gy intensity-modulated radiotherapy (IMRT), 2 Gy/day in 30 fractions (5 days a week for 6 weeks).","id":"FG000","title":"IMRT"},{"description":"Radiation therapy (RT): 60 Gy IMRT, 2 Gy/day in 30 fractions (5 days a week for 6 weeks).\n\nCetuximab: 400 mg/m\\^2 intravenously (IV) at least 5 days prior to IMRT; 250 mg/m\\^2 IV once a week for 6 weeks during RT and continuing 4 weeks after RT.","id":"FG001","title":"IMRT Plus Cetuximab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"23"}],"type":"Protocol Violation"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"314"},{"groupId":"FG001","numSubjects":"313"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"287"},{"groupId":"FG001","numSubjects":"290"}],"type":"Eligible"},{"achievements":[{"groupId":"FG000","numSubjects":"282"},{"groupId":"FG001","numSubjects":"276"}],"comment":"Adverse event population","type":"Eligible and Started Protocol Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"287"},{"groupId":"FG001","numSubjects":"290"}],"comment":"Participants contributing data to results are considered to have completed the study.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"23"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"After trial registration, tissue slides from the tumor specimen were sent to the NRG Oncology biorepository for immunohistochemical analysis of epidermal growth factor receptor (EGFR) expression and (for oropharynx cancer) p16, a surrogate biomarker for human papillomavirus (HPV) positivity. From 702 registered participants, 627 were randomized."}